Premium
Therapeutic potential of nucleotides in the eye
Author(s) -
Pintor Jesús,
Peral Assumpta
Publication year - 2001
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.1115
Subject(s) - intraocular pressure , receptor , antagonist , chemistry , pharmacology , nucleotide , cholinergic , receptor antagonist , endocrinology , p2y receptor , medicine , biochemistry , agonist , ophthalmology , gene
Adenine mononucleotides present the ability to produce changes in the intraocular pressure in New Zealand rabbits. Two main groups of compounds were found in terms of their behaviour—on the one hand, those that increased intraocular pressure, and on the other hand, those that reduced it. The hypotensive compounds showed a concentration–response behaviour, and were blocked by the P2 receptor antagonist pyridoxalphosphate‐6‐azophenyl‐2′,4′‐disulfonic acid. Moreover, the hypotensive compounds were unaffected by the pretreatment with sympathetic antagonists but were completely abolished by the parasympathetic antagonists. This fact suggests the possibility of these P2 receptors to be present at the cholinergic terminal that control intraocular pressure. Adenine mononucleotides also were assayed in their ability to increase tear secretion rate. This study showed that tear secretion is stimulated via P2Y 2 receptors. Drug Dev. Res. 52:190–195, 2001. © 2001 Wiley‐Liss, Inc.